Liposomal delivery of gene therapy for ovarian cancer: a systematic review

Reproductive Biology and Endocrinology

Review

Madison Pereira¹  Kathy Matuszewska¹  Maria Xiao²  Sunny Kim²  Toney Lieu²  Jin Sung Son²  Helena Kim²  Jim Petrik³  David Le Nguyen⁴  Ryan Chow⁴ 

[1] Department of Biomedical Sciences, University of Guelph, Guelph, ON, Canada;Faculty of Health Sciences, University of McMaster, Hamilton, ON, Canada;Faculty of Health Sciences, University of McMaster, Hamilton, ON, Canada;Department of Biomedical Sciences, University of Guelph, Guelph, ON, Canada;Department of Obstetrics and Gynecology, University of McMaster, Hamilton, ON, Canada;Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada;

关键词: Ovarian cancer;    Liposomes;    Gene therapy;    micro RNAs;   

DOI  :  10.1186/s12958-023-01125-2

 received in 2023-05-30, accepted in 2023-08-07,  发布年份 2023

来源: Springer

【 摘 要 】

ObjectiveTo systematically identify and narratively synthesize the evidence surrounding liposomal delivery of gene therapy and the outcome for ovarian cancer.MethodsAn electronic database search of the Embase, MEDLINE and Web of Science from inception until July 7, 2023, was conducted to identify primary studies that investigated the effect of liposomal delivery of gene therapy on ovarian cancer outcomes. Retrieved studies were assessed against the eligibility criteria for inclusion.ResultsThe search yielded 564 studies, of which 75 met the inclusion criteria. Four major types of liposomes were identified: cationic, neutral, polymer-coated, and ligand-targeted liposomes. The liposome with the most evidence involved cationic liposomes which are characterized by their positively charged phospholipids (n = 37, 49.3%). Similarly, those with neutrally charged phospholipids, such as 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, were highly researched as well (n = 25, 33.3%). Eight areas of gene therapy research were identified, evaluating either target proteins/transcripts or molecular pathways: microRNAs, ephrin type-A receptor 2 (EphA2), interleukins, mitogen-activated protein kinase (MAPK), human-telomerase reverse transcriptase/E1A (hTERT/EA1), suicide gene, p53, and multidrug resistance mutation 1 (MDR1).ConclusionLiposomal delivery of gene therapy for ovarian cancer shows promise in many in vivo studies. Emerging polymer-coated and ligand-targeted liposomes have been gaining interest as they have been shown to have more stability and specificity. We found that gene therapy involving microRNAs was the most frequently studied. Overall, liposomal genetic therapy has been shown to reduce tumor size and weight and improve survivability. More research involving the delivery and targets of gene therapy for ovarian cancer may be a promising avenue to improve patient outcomes.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

40517_2023_261_Article_IEq17.gif

13690_2023_1154_Article_IEq18.gif

40517_2023_261_Article_IEq2.gif

13690_2023_1154_Article_IEq2.gif

12974_2023_2864_Article_IEq1.gif